Rivaroxaban: A review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation

Drugs

Volumn 73, Issue 7, 2013, Pages 715-739

  Carter, Natalie J ^a   Plosker, Greg L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACTIVATED PROTHROMBIN COMPLEX; AMIODARONE; ATORVASTATIN; CARBAMAZEPINE; CLOPIDOGREL; DABIGATRAN ETEXILATE; DIGOXIN; DILTIAZEM; DRONEDARONE; ENOXAPARIN; ERYTHROMYCIN; ITRACONAZOLE; KETOCONAZOLE; MIDAZOLAM; NAPROXEN; OMEPRAZOLE; PHENOBARBITAL; PHENYTOIN; POSACONAZOLE; PROTHROMBIN COMPLEX; QUINIDINE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIFAMPICIN; RITONAVIR; RIVAROXABAN; VERAPAMIL; VORICONAZOLE; WARFARIN;

ANTICOAGULATION; BLEEDING; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG SAFETY; DRUG TOLERABILITY; EMBOLISM; EPISTAXIS; GASTROINTESTINAL HEMORRHAGE; GINGIVA BLEEDING; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEMATURIA; HUMAN; INTERNATIONAL NORMALIZED RATIO; PNEUMONIA; QT INTERVAL; REVIEW; SYSTEMIC EMBOLISM; THROMBOCYTE AGGREGATION;

ANTICOAGULANTS; ATRIAL FIBRILLATION; COST-BENEFIT ANALYSIS; DRUG INTERACTIONS; EMBOLISM; HUMANS; MORPHOLINES; STROKE; THIOPHENES;

EID: 84878625563     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0056-9     Document Type: Review

References (134)

1. You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e531S-75S.
2. Chiang C-E, Naditch-Brûlé L, Murin J, et al. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the RealiseAF international registry. Circ Arrhythm Electrophysiol. 2012;5(4):632-9.
3. Naccarelli GV, Varker H, Lin J, et al. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009;104:1534-9.
4. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119-25.
5. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA. 2001;285(18):2370-5.
6. Murphy NF, Simpson CR, Jhund PS, et al. A national survey of the prevalence, incidence, primary care burden and treatment of atrial fibrillation in Scotland. Heart. 2007;93:606-12.
7. Stewart S, Hart CL, Hole DJ, et al. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart. 2001;86:516-21.
8. Stefansdottir H, Aspelund T, Gudnason V, et al. Trends in the incidence and prevalence of atrial fibrillation in Iceland and future projections. Europace. 2011;13(8):1110-7.
9. Camm AJ, Kirchhof P, Lip GYH, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369-429.
10. Menke J, Lüthje L, Kastrup A, et al. Thromboembolism in atrial fibrillation. Am J Cardiol. 2010;105:502-10.
11. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke. 1991;22:983-8.
12. Lin H-J, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation: the Framingham study. Stroke. 1996;27:1760-4.
13. Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke. 2005;36:1115-9.
14. Andreotti F, Camm J, Dávalos A, et al. How can we avoid a stroke crisis in Europe? Working group report: prevention of atrial fibrillation-related stroke. 2012. http://www.afa-international.org/files/file/ How%20Can%20We%20Avoid%20a%20Stroke%20Crisis%20in%20Europe- Updated%20EU%20Report.pdf. Accessed 10 Apr 2013.
15. Granger CB, Armaganijan LV. Newer oral anticoagulants should be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism. Circulation. 2012;125(1):159-64.
16. ® (rivaroxaban): EU summary of product characteristics. 2013. http://www.ema.europa.eu/docs/en-GB/document- library/EPAR-Product-Information/human/000944/WC500057108.pdf. Accessed 10 Apr 2013.
17. National Institute for Health and Clinical Excellence. Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation: NICE technology appraisal guidance 256. 2012. http://www.nice.org. uk/nicemedia/live/13746/59295/59295.pdf. Accessed 10 Apr 2013.
18. ® (rivaroxaban): US prescribing information. 2013. http://www.janssenpharmaceuticalsinc.com/assets/ xareltopi.pdf. Accessed 10 Apr 2013.
19. ® (rivaroxaban): Canadian product monograph. 2012. http://www.bayer.ca/files/XARELTO-PM-ENG-18JUL2012-154961-0. pdf?#. Accessed 10 Apr 2013.
20. ® (rivaroxaban): Japanese prescribing information. Osaka: Bayer Yakuhin Co. Ltd; 2012.
21. Camm AJ, Lip GYH, De Caterina R, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation: developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719-47.
22. ® (rivaroxaban): CHMP assessment report. 2008. http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Public-assessment-report/human/000944/WC500057122.pdf. Accessed 10 Apr 2013.
23. Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939: an oral, direct factor Xa inhibitor. J Thromb Haemost. 2005;3(3):514-21.
24. Roehrig S, Straub A, Pohlmann J, et al. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]- 1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J Med Chem. 2005;48(19):5900-8.
25. Laux V, Perzborn E, Kubitza D, et al. Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor. Semin Thromb Hemost. 2007;33(5):515-23.
26. Duggan ST. Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery. Am J Cardiovasc Drugs. 2012;12(1):57-72.
27. Duggan ST, Scott LJ, Plosker GL. Rivaroxaban: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery. Drugs. 2009;69(13):1829-51.
28. Molenaar PJ, Dinkelaar J, Leyte A. Measuring rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generation. Clin Chem Lab Med. 2012;50(10):1799-807.
29. Lindhoff-Last E, Samama MM, Ortel TL, et al. Assays for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit. 2010;32(6):673-9.
30. Turpie AGG, Kreutz R, Llau J, et al. Management consensus guidance for the use of rivaroxaban - an oral, direct factor Xa inhibitor. Thromb Haemost. 2012;108:876-86.
31. Miyares MA, Davis K. Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient. Am J Health Syst Pharm. 2012;69:1473-84.
32. Baglin T, Hillarp A, Tripodi A, et al. Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society of Thrombosis and Haemostasis. J Thromb Haemost. 2013;11(4):756-60.
33. Rohde G. Determination of rivaroxaban - a novel, oral, direct factor Xa inhibitor - in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;872:43-50.
34. Mani H, Rohde G, Stratmann G, et al. Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin. Thromb Haemost. 2012;108:191-8.
35. Siegal DM, Crowther MA. Acute management of bleeding in patients on novel oral anticoagulants. Eur Heart J. 2013;34(7):489-498b.
36. Hillarp A, Baghaei F, Fagerberg Blixter I, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost. 2011;9:133-9.
37. Samama MM, Martinoli J-L, LeFlem L, et al. Assessment of laboratory assays to measure rivaroxaban - an oral, direct factor Xa inhibitor. Thromb Haemost. 2010;103:815-25.
38. Mani H, Hesse C, Stratmann G, et al. Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time. Thromb Haemost. 2011;106:156-64.
39. Barrett YC, Wang Z, Frost C, et al. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost. 2010;104:1263-71.
40. Asmis LM, Alberio L, Angelillo-Scherrer A, et al. Rivaroxaban: quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories. Thromb Res. 2012;129:492-8.
41. Samama MM, Contant G, Spiro TE, et al. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost. 2012;107:379-87.
42. Harenberg J, Krämer R, Giese C, et al. Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability. J Thromb Thrombolysis. 2011;32:267-71.
43. Kubitza D, Mueck W, Becka M. Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation. Drug Saf. 2008;31(1):67-77.
44. Kopecky S. New anticoagulants for stroke prophylaxis in atrial fibrillation: assessing the impact on medication adherence. Am J Cardiovasc Drugs. 2012;12(5):287-94.
45. Ansell J. New oral anticoagulants should not be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation. Circulation. 2012;125(1):165-70.
46. Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124(14):1573-9.
47. Marlu R, Hodaj E, Paris A, et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost. 2012;108(2):217-24.
48. Kubitza D, Becka M, Mueck W, et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct factor Xa inhibitor. Br J Clin Pharmacol. 2010;70(5):703-12.
49. Mueck W, Lensing AWA, Agnelli G, et al. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet. 2011;50(10):675-86.
50. ® (rivaroxaban): EMA assessment report. 2011. http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Assessment-Report-Variation/human/000944/WC500120735.pdf. Accessed 10 Apr 2013.
51. Kubitza D, Becka M, Wensing G, et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct factor Xa inhibitor - after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005;61(12):873-80.
52. 2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol. 2006;46(5):549-58.
53. Hori M, Matsumoto M, Tanahashi N, et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation: the J-ROCKET AF study. Circ J. 2012;76(9):2104-11.
54. Tanigawa R, Kaneko M, Hashizume K, et al. Model-based dose selection for phase III rivaroxaban study in Japanese patients with non-valvular atrial fibrillation. Drug Metab Pharmacokinet. 2013;28(1):59-70.
55. Kaneko M, Tanigawa T, Hashizume K, et al. Confirmation of model-based dose selection for Japanese phase III study of rivaroxaban in nonvalvular atrial fibrillation patients. Drug Metab Pharmacokinet. 2013. doi: 10.2133/dmpk.DMPK-12-RG-109.
56. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-91.
57. ROCKET AF Study Investigators. Rivaroxaban: once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF study. Am Heart J. 2010;159(3):340-7.e1.
58. Halperin JL, Wojdyla D, Piccini JP, et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the ROCKET-AF trial [abstract no. 148]. Stroke. 2012;43(2 Suppl.).
59. Hankey GJ, Patel MR, Stevens SR, et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol. 2012;11(4):315-22.
60. Halperin JL, Bloomgarden Z, Hellkamp A, et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and diabetes: a subgroup analysis of the ROCKET AF trial [abstract no. 15544]. Circulation. 2012;126(21 Suppl.).
61. van Diepen S, Hellkamp AS, Patel MR, et al. Rivaroxaban is associated with a reduced risk of thromboembolic events and hemorrhagic stroke in patient with heart failure: insights from ROCKET AF [abstract no. 14365]. Circulation. 2012;126(21 Suppl.).
62. Piccini JP, Stevens S, Lokhnygina Y, et al. Outcomes following cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial [abstract no. 19281]. Circulation. 2012;126(21 Suppl.).
63. Patel MR, Hellkamp AS, Lokhnygina Y, et al. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation. J Am Coll Cardiol. 2013;61(6):651-8.
64. Singer DE, Hellkamp AS, Piccini JP, et al. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc. 2013;2(1):e000067.
65. Fox KAA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32(19):2387-94.
66. Japanese Circulation Society Joint Working Groups. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008): revised English digest version. 2008. http://www.j-circ.or.jp/english/activities/pdf/gl/satoshi- ogawa2008.pdf. Accessed 10 Apr 2013.
67. Tanahashi N, Hori M, Matsumoto M, et al. Rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation for the secondary prevention of stroke: a subgroup analysis of J-ROCKET AF. J Stroke Cerebrovasc Dis. 2013. doi: 10.1016/j.jstrokecerebrovasdis.2012.12.010.
68. Hori M, Matsumoto M, Tanahashi N, et al. Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation: subanalysis of J-ROCKET AF for patients with moderate renal impairment. Circ J. 2013;77(3):632-8.
69. ® (rivaroxaban): CDER medical review. 2009. http://www.accessdata.fda.gov/ drugsatfda-docs/nda/2011/202439Orig1s000MedR.pdf. Accessed 10 Apr 2013.
70. Nessel C, Mahaffey K, Piccini J, et al. Incidence and outcomes of gastrointestinal hemorrhage in patients with atrial fibrillation treated with rivaroxaban or warfarin: results from the ROCKET AF trial [abstract]. Chest. 2012;142(4 Suppl.):84A.
71. Lee S, Anglade MW, Pham D, et al. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Am J Cardiol. 2012;110(6):845-51.
72. Kansal AR, Sharma M, Bradley-Kennedy C, et al. Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Thromb Haemost. 2012;108:672-82.
73. ®): SMC advisory document. 2012. http://www.scottishmedicines.org.uk/files/advice/rivaroxaban-Xarelto-for-AF- FINAL-Jan-2012-for-website.pdf. Accessed 11 Apr 2013.
74. Wells G, Coyle D, Cameron C, et al. Safety, effectiveness, and cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation: therapeutic review. 2012. http://www.cadth.ca/media/pdf/NOAC- Therapeutic-Review-final-report.pdf. Accessed 11 Apr 2013.
75. Asukai Y, Duran A, Lloyd A, et al. Cost-effectiveness of rivaroxaban for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors: a UK perspective [abstract no. PCV51]. Value Health. 2012;15(7):A371.
76. Skanes AC, Healey JS, Cairns JA, et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol. 2012;28(2):125-36.
77. ® (apixaban): EU summary of product characteristics. 2012. http://www.ema.europa.eu/docs/en- GB/document-library/EPAR-Product-Information/human/002148/WC500107728.pdf. Accessed 11 Apr 2013.
78. ® (apixaban): highlights of US prescribing information. 2012. http://www.accessdata.fda.gov/ drugsatfda-docs/label/2012/202155s000lbl.pdf. Accessed 11 Apr 2013.
79. Garnock-Jones KP. Dabigatran etexilate: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Am J Cardiovasc Drugs. 2011;11(1):57-72.
80. ® (dabigatran etexilate) 110 and 150 mg capsules: EU summary of product characteristics. 2013. http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/000829/WC500041059.pdf. Accessed 11 Apr 2013.
81. ® (dabigatran etexilate): US prescribing information. 2012. http://www.accessdata. fda.gov/drugsatfda-docs/label/2012/022512s016lbl.pdf. Accessed 11 Apr 2013.
82. National Institute for Health and Clinical Excellence. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: final appraisal determination. 2011. http://www.nice.org.uk/ nicemedia/live/12225/56899/56899.pdf. Accessed 11 Apr 2013.
83. National Institute for Health and Clinical Excellence. Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation: NICE technology appraisal guidance 275. 2013. http://www.nice.org. uk/nicemedia/live/14086/62874/62874.pdf. Accessed 11 Apr 2013.
84. Ranganathan RLN, Venkatesh P. Atrial fibrillation and stroke prevention: is warfarin still an option? - No. J Neural Transm. 2012. doi: 10.1007/s00702-012-0943-3.
85. Cairns JA. Prevention of stroke and systemic embolization in atrial fibrillation: a Canadian perspective. Pol Arch Med Wewn. 2012;122(9):428-36.
86. Wisler JW, Becker RC. A guidance pathway for the selection of novel anticoagulants in the treatment of atrial fibrillation. Crit Pathw Cardiol. 2012;11(2):55-61.
87. Schulman S, Crowther MA. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood. 2012;119(13):3016-23.
88. Niessner A. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation [letter]. N Engl J Med. 2011;365(24):2333.
89. del Zoppo GJ, Eliasziw M. New options in anticoagulation for atrial fibrillation. N Engl J Med. 2011;365(10):952-3.
90. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med. 2010;152(11):726-32.
91. Lesaffre E. Superiority, equivalence, and non-inferiority trials. Bull NYU Hosp Jt Dis. 2008;66(2):150-4.
92. Patel MR, Fox KAA, Califf RM. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation [letter]. N Engl J Med. 2011;365(24):2335.
93. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92.
94. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51.
95. Harenberg J, Marx S, Diener H-C, et al. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis. Int Angiol. 2012;31:330-9.
96. Lip GYH, Larsen TB, Graungaard T, et al. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol. 2012;60(8):738-46.
97. Mantha S, Ansell J. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Thromb Haemost. 2012;108:476-84.
98. Rasmussen LH, Larsen TB, Graungaard T, et al. Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis. Br Med J. 2012;345:e7097.
99. Baker WL, Phung OJ. Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2012;5:711-9.
100. Testa L, Agnifili M, Latini RA, et al. Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation. Q J Med. 2012;105:949-57.
101. Schneeweiss S, Gagne JJ, Patrick AR, et al. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2012;5:480-6.
102. BMJ-Technology Assessment Group. Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation: ERG's response to Bayer's comments on ACD. 2012. http://www.nice.org.uk/nicemedia/live/13308/ 58739/58739.pdf. Accessed 11 Apr 2013.
103. Harenberg J, Weiss C. Clinical trials with new oral anticoagulants: additive value of indirect comparisons also named network meta-analyses. Hämostaseologie. 2013;33(1):62-70.
104. Cucherat M. Bias-corrected indirect comparison meta-analysis of new oral anticoagulant in atrial fibrillation [abstract no. PCV15]. Value Health. 2012;15(7):A364. Plus poster presented at the 15th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; 3-7 Nov 2012; Berlin.
105. Mega JL. A new era for anticoagulation in atrial fibrillation. N Engl J Med. 2011;365(11):1052-4.
106. Banerjee A, Lane DA, Torp-Pedersen C, et al. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost. 2012;107:584-9.
107. Lee S, Monz BU, Clemens A, et al. Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation in the United Kingdom: a cross-sectional analysis using the General Practice Research Database. BMJ Open. 2012;2(6):e001768.
108. Granger CB, Alexander JH, Hanna M, et al. Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial [abstract no. 4045]. Eur Heart J. 2012;33(Suppl.):685-6.
109. Rosenstein R, Parra D. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation [letter]. N Engl J Med. 2011;365(24):2334.
110. Fleming TR, Emerson SS. Evaluating rivaroxaban for nonvalvular atrial fibrillation: regulatory considerations. N Engl J Med. 2011;365(17):1557-9.
111. Rose A. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation [letter]. N Engl J Med. 2011;365(24):2333-4.
112. Baumann Kreuziger LM, Morton CT, Dries DJ. New anticoagulants: a concise review. J Trauma Acute Care Surg. 2012;73(4):983-92.
113. Marlu R, Hodaj E, Pernod G. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects [letter]. Circulation. 2012;125(16):e615.
114. Eerenberg ES, Sijpkens MK, Meijers JCM, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects [letter]. Circulation. 2012;125(16):e616.
115. Deedwania PC, Huang GW. Role of emerging antithrombotic therapy in the prevention of cardioembolic complications in patients with atrial fibrillation. Am J Cardiovasc Drugs. 2011;11(4):265-75.
116. Depasse F, Busson J, Mnich J, et al. Effect of BAY 59-7939 - a novel, oral, direct factor Xa inhibitor - on clot-bound factor Xa activity in vitro [abstract no. P1104]. J Thromb Haemost. 2005;3(Suppl. 1).
117. Gerotziafas GT, Baccouche H, Sassi M, et al. Optimisation of the assays for the measurement of clotting factor activity in the presence of rivaroxaban [letter]. Thromb Res. 2012;129:101-3.
118. Tichelaar V, de Jong H, Nijland H, et al. Interference of rivaroxaban in one-stage and chromogenic factor VIII:C assays [letter]. Thromb Haemost. 2011;106:990-2.
119. Mani H, Hesse C, Stratmann G, et al. Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions. Thromb Haemost. 2013;109(1):127-36.
120. Kubitza D, Becka M, Voith B, et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther. 2005;78(4):412-21.
121. Mueck W, Becka M, Kubitza D, et al. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct factor Xa inhibitor - in healthy subjects. Int J Clin Pharmacol Ther. 2007;45(6):335-44.
122. Mueck W, Eriksson BI, Bauer KA, et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct factor Xa inhibitor - in patients undergoing major orthopaedic surgery. Clin Pharmacokinet. 2008;47(3):203-16.
123. Gerotziafas GT, Elalamy I, Depasse F, et al. In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban. J Thromb Haemost. 2007;5(4):886-8.
124. Varin R, Mirshahi S, Mirshahi P, et al. Whole blood clots are more resistant to lysis than plasma clots: greater efficacy of rivaroxaban. Thromb Res. 2013;131:e100-9.
125. Graff J, von Hentig N, Misselwitz F, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J Clin Pharmacol. 2007;47(11):1398-407.
126. Freyburger G, Macouillard G, Labrouche S, et al. Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb Res. 2011;127:457-65.
127. Wong PC, Crain EJ, Watson CA, et al. Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits. J Thromb Haemost. 2009;7(8):1313-20.
128. Perzborn E, Lange U. Rivaroxaban - an oral, direct factor Xa inhibitor - inhibits tissue factor-mediated platelet aggregation [abstract no. P-W-642]. J Thromb Haemost. 2007;5(Suppl. 2).
129. Harenberg J, Marx S, Krämer R, et al. Determination of an international sensitivity index of thromboplastin reagents using a WHO thromboplastin as calibrator for plasma spiked with rivaroxaban. Blood Coagul Fibrinolysis. 2011;22:637-41.
130. Harenberg J, Marx S, Weiss C, et al. Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban. J Thromb Haemost. 2012;10:1433-6.
131. Harder S, Parisius J, Picard-Willems B. Monitoring direct FXa-inhibitors and fondaparinux by prothrombinase-induced clotting time (PiCT): relation to FXa-activity and influence of assay modifications. Thromb Res. 2008;123:396-403.
132. Mueck W, Borris LC, Dahl OE, et al. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost. 2008;100(3):453-61.
133. Van Os GMA, De Laat B, Kamphuisen PW, et al. Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time [letter]. J Thromb Haemost. 2011;9:1657-9.
134. Merriman E, Kaplan Z, Butler J, et al. Rivaroxaban and false positive lupus anticoagulant testing [letter]. Thromb Haemost. 2011;105:385-6.